BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 30357576)

  • 21. Intraductal papillary mucinous neoplasms of the pancreas: an updated experience.
    Sohn TA; Yeo CJ; Cameron JL; Hruban RH; Fukushima N; Campbell KA; Lillemoe KD
    Ann Surg; 2004 Jun; 239(6):788-97; discussion 797-9. PubMed ID: 15166958
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct pathways of pathogenesis of intraductal oncocytic papillary neoplasms and intraductal papillary mucinous neoplasms of the pancreas.
    Basturk O; Chung SM; Hruban RH; Adsay NV; Askan G; Iacobuzio-Donahue C; Balci S; Zee SY; Memis B; Shia J; Klimstra DS
    Virchows Arch; 2016 Nov; 469(5):523-532. PubMed ID: 27591765
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of pancreatic cancers during long-term follow-up of side-branch intraductal papillary mucinous neoplasms.
    Sawai Y; Yamao K; Bhatia V; Chiba T; Mizuno N; Sawaki A; Takahashi K; Tajika M; Shimizu Y; Yatabe Y; Yanagisawa A
    Endoscopy; 2010 Dec; 42(12):1077-84. PubMed ID: 21120776
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Loss of Trefoil Factor 2 From Pancreatic Duct Glands Promotes Formation of Intraductal Papillary Mucinous Neoplasms in Mice.
    Yamaguchi J; Mino-Kenudson M; Liss AS; Chowdhury S; Wang TC; Fernández-Del Castillo C; Lillemoe KD; Warshaw AL; Thayer SP
    Gastroenterology; 2016 Dec; 151(6):1232-1244.e10. PubMed ID: 27523981
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chondroitin sulfate proteoglycan CSPG4 as a novel hypoxia-sensitive marker in pancreatic tumors.
    Keleg S; Titov A; Heller A; Giese T; Tjaden C; Ahmad SS; Gaida MM; Bauer AS; Werner J; Giese NA
    PLoS One; 2014; 9(6):e100178. PubMed ID: 24932730
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Characteristic clinicopathological features of the types of intraductal papillary-mucinous neoplasms of the pancreas.
    Ishida M; Egawa S; Aoki T; Sakata N; Mikami Y; Motoi F; Abe T; Fukuyama S; Sunamura M; Unno M; Moriya T; Horii A; Furukawa T
    Pancreas; 2007 Nov; 35(4):348-52. PubMed ID: 18090241
    [TBL] [Abstract][Full Text] [Related]  

  • 27. ARID1A Maintains Differentiation of Pancreatic Ductal Cells and Inhibits Development of Pancreatic Ductal Adenocarcinoma in Mice.
    Kimura Y; Fukuda A; Ogawa S; Maruno T; Takada Y; Tsuda M; Hiramatsu Y; Araki O; Nagao M; Yoshikawa T; Ikuta K; Yoshioka T; Wang Z; Akiyama H; Wright CV; Takaori K; Uemoto S; Chiba T; Seno H
    Gastroenterology; 2018 Jul; 155(1):194-209.e2. PubMed ID: 29604291
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pancreatic ductal adenocarcinoma derived from IPMN and pancreatic ductal adenocarcinoma concomitant with IPMN.
    Yamaguchi K; Kanemitsu S; Hatori T; Maguchi H; Shimizu Y; Tada M; Nakagohri T; Hanada K; Osanai M; Noda Y; Nakaizumi A; Furukawa T; Ban S; Nobukawa B; Kato Y; Tanaka M
    Pancreas; 2011 May; 40(4):571-80. PubMed ID: 21499212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Proposed Nomogram Predicting the Individual Risk of Malignancy in the Patients With Branch Duct Type Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Jang JY; Park T; Lee S; Kim Y; Lee SY; Kim SW; Kim SC; Song KB; Yamamoto M; Hatori T; Hirono S; Satoi S; Fujii T; Hirano S; Hashimoto Y; Shimizu Y; Choi DW; Choi SH; Heo JS; Motoi F; Matsumoto I; Lee WJ; Kang CM; Han HS; Yoon YS; Sho M; Nagano H; Honda G; Kim SG; Yu HC; Chung JC; Nagakawa Y; Seo HI; Yamaue H
    Ann Surg; 2017 Dec; 266(6):1062-1068. PubMed ID: 27607098
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Is the intraductal papillary mucinous neoplasia of the biliary tract a counterpart of pancreatic papillary mucinous neoplasm?
    Klöppel G; Kosmahl M
    J Hepatol; 2006 Feb; 44(2):249-50. PubMed ID: 16360969
    [No Abstract]   [Full Text] [Related]  

  • 31. Assessment of a Revised Management Strategy for Patients With Intraductal Papillary Mucinous Neoplasms Involving the Main Pancreatic Duct.
    Sugimoto M; Elliott IA; Nguyen AH; Kim S; Muthusamy VR; Watson R; Hines OJ; Dawson DW; Reber HA; Donahue TR
    JAMA Surg; 2017 Jan; 152(1):e163349. PubMed ID: 27829085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intraductal papillary mucinous neoplasm (IPMN) of the pancreas: its histopathologic difference between 2 major types.
    Ban S; Naitoh Y; Mino-Kenudson M; Sakurai T; Kuroda M; Koyama I; Lauwers GY; Shimizu M
    Am J Surg Pathol; 2006 Dec; 30(12):1561-9. PubMed ID: 17122512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinicopathological and prognostic significance of MUC13 and AGR2 expression in intraductal papillary mucinous neoplasms of the pancreas.
    Mito K; Saito M; Morita K; Maetani I; Sata N; Mieno M; Fukushima N
    Pancreatology; 2018 Jun; 18(4):407-412. PubMed ID: 29650332
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Diminished Immune Surveillance during Histologic Progression of Intraductal Papillary Mucinous Neoplasms Offers a Therapeutic Opportunity for Cancer Interception.
    Hernandez S; Parra ER; Uraoka N; Tang X; Shen Y; Qiao W; Jiang M; Zhang S; Mino B; Lu W; Pandurengan R; Haymaker C; Affolter K; Scaife CL; Yip-Schneider M; Schmidt CM; Firpo MA; Mulvihill SJ; Koay EJ; Wang H; Wistuba II; Maitra A; Solis LM; Sen S
    Clin Cancer Res; 2022 May; 28(9):1938-1947. PubMed ID: 35491652
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A comparison between intraductal papillary neoplasms of the biliary tract (BT-IPMNs) and intraductal papillary mucinous neoplasms of the pancreas (P-IPMNs) reveals distinct clinical manifestations and outcomes.
    Minagawa N; Sato N; Mori Y; Tamura T; Higure A; Yamaguchi K
    Eur J Surg Oncol; 2013 Jun; 39(6):554-8. PubMed ID: 23506840
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Diagnosis and differential diagnosis of intraductal papillary mucinous neoplasm of pancreas].
    Ji Y; Tan YS; Zhu XZ; Zeng HY; Kuang TT; Jin DY
    Zhonghua Bing Li Xue Za Zhi; 2006 Feb; 35(2):77-81. PubMed ID: 16630480
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of MSX2 predicts malignancy of branch duct intraductal papillary mucinous neoplasm of the pancreas.
    Satoh K; Hamada S; Kanno A; Hirota M; Umino J; Ito H; Masamune A; Egawa S; Unno M; Shimosegawa T
    J Gastroenterol; 2010 Jul; 45(7):763-70. PubMed ID: 20107842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pancreatic main-duct involvement in branch-duct IPMNs: an underestimated risk.
    Fritz S; Klauss M; Bergmann F; Strobel O; Schneider L; Werner J; Hackert T; Büchler MW
    Ann Surg; 2014 Nov; 260(5):848-55; discussion 855-6. PubMed ID: 25379856
    [TBL] [Abstract][Full Text] [Related]  

  • 39. REG4 is associated with carcinogenesis in the 'intestinal' pathway of intraductal papillary mucinous neoplasms.
    Nakata K; Nagai E; Ohuchida K; Aishima S; Hayashi A; Miyasaka Y; Yu J; Mizumoto K; Tanaka M; Tsuneyoshi M
    Mod Pathol; 2009 Mar; 22(3):460-8. PubMed ID: 19136934
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeted DNA Sequencing Reveals Patterns of Local Progression in the Pancreatic Remnant Following Resection of Intraductal Papillary Mucinous Neoplasm (IPMN) of the Pancreas.
    Pea A; Yu J; Rezaee N; Luchini C; He J; Dal Molin M; Griffin JF; Fedor H; Fesharakizadeh S; Salvia R; Weiss MJ; Bassi C; Cameron JL; Zheng L; Scarpa A; Hruban RH; Lennon AM; Goggins M; Wolfgang CL; Wood LD
    Ann Surg; 2017 Jul; 266(1):133-141. PubMed ID: 27433916
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.